Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion

Journal of Neuroscience Research

Volumn 88, Issue 4, 2010, Pages 807-815

  Wang, Juan ^a   Zhang, Hai Yan ^a   Tang, Xi Can ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cerebral hypoperfusion; Chronic hypoxia; Huperzine A; Inflammation; White matter

Indexed keywords

HUPERZINE A; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; BRAIN HYPOXIA; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

ANIMALS; ANTIGENS, CD11B; CAROTID ARTERY DISEASES; CELL HYPOXIA; CEREBRAL CORTEX; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; MAZE LEARNING; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYELIN SHEATH; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; TIME FACTORS; TISSUE THERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76549112494     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22237     Document Type: Article

References (73)

1. Birks J. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1:CD005593.
2. Bonner LT, Peskind ER. 2002. Pharmacologic treatments of dementia. Med Clin North Am 86:657-674.
3. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405:458-462.
4. Chen YP, Mei YW, Chen SQ. 2002. Treatment of multi-infarct dementia with huperzine A. Herald Med 21:275-276.
5. Cho KO, La HO, Cho YJ, Sung KW, Kim SY. 2006. Minocycline attenuates white matter damage in a rat model of chronic cerebral hypoperfusion. J Neurosci Res 83:285-291.
6. Conejero-Goldberg C, Davies P, Ulloa L. 2008. Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. Neurosci Biobehav Rev 32:693-706.
7. Davidson CM, Pappas BA, Stevens WD, Fortin T, Bennett SA. 2000. Chronic cerebral hypoperfusion: loss of pupillary reflex, visual impairment and retinal neurodegeneration. Brain Res 859:96-103.
8. de la Torre JC. 2000. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 21:331-342.
9. Deng Y, Lu J, Sivakumar V, Ling EA, Kaur C. 2008. Amoeboid microglia in the periventricular white matter induce oligodendrocyte damage through expression of proinflammatory cytokines via MAP kinase signaling pathway in hypoxic neonatal rats. Brain Pathol 18:387-400.
10. Erkinjuntti T, Roman G, Gauthier S. 2004. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 226:63-66.
11. Farkas E, Donka G, de Vos RA, Mihaly A, Bari F, Luiten PG. 2004a. Experimental cerebral hypoperfusion induces white matter injury and microglial activation in the rat brain. Acta Neuropathol 108:57-64.
12. Farkas E, Institoris A, Domoki F, Mihaly A, Luiten PG, Bari F. 2004b. Diazoxide and dimethyl sulphoxide prevent cerebral hypoperfusion-related learning dysfunction and brain damage after carotid artery occlusion. Brain Res 1008:252-260.
13. Farkas E, Luiten PG, Bari F. 2007. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusionrelated neurodegenerative diseases. Brain Res Rev 54:162-180.
14. Haddad EB, Birrell M, McCluskie K, Ling A, Webber SE, Foster ML, Belvisi MG. 2001. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br J Pharmacol 132:1715-1724.
15. Hommes DW, Peppelenbosch MP, van Deventer SJ. 2003. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52:144-151.
16. Irving EA, Bamford M. 2002. Role of mitogen- and stress-activated kinases in ischemic injury. J Cereb Blood Flow Metab 22:631-647.
17. Khwaja O, Volpe JJ. 2008. Pathogenesis of cerebral white matter injury of prematurity. Arch Dis Child Fetal Neonatal Ed 93:F153-161.
18. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. 2006. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthritis Rheum 54:2745-2756.
19. Kumar S, Boehm J, Lee JC. 2003. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2:717-726.
20. Lee YB, Schrader JW, Kim SU. 2000. p38 MAP kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine 12:874-880.
21. MH, Miao ZH, Tan WF, Yue JM, Zhang C, Lin LP, Zhang XW, Ding J. 2004. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clin Cancer Res 10:8266-8274.
22. Lin S, Cox HJ, Rhodes PG, Cai Z. 2006. Neuroprotection of alpha-phenyl-n-tert-butyl-nitrone on the neonatal white matter is associated with anti-inflammation. Neurosci Lett 405:52-56.
23. Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B. 2007. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J 21:61-73.
24. Liu R, Wen Y, Perez E, Wang X, Day AL, Simpkins JW, Yang SH. 2005. 17Beta-estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female rats. Brain Res 1060:55-61.
25. Masumura M, Hata R, Nagai Y, Sawada T. 2001. Oligodendroglial cell death with DNA fragmentation in the white matter under chronic cerebral hypoperfusion: comparison between normotensive and spontaneously hypertensive rats. Neurosci Res 39:401-412.
26. McCoy MK, Tansey MG. 2008. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45.
27. Minami M, Katayama T, Satoh M. 2006. Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci 100:461-470.
28. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. 2006. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 50:540-547.
29. Nizri E, Irony-Tur-Sinai M, Faranesh N, Lavon I, Lavi E, Weinstock M, Brenner T. 2008. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 203:12-22.
30. Ohta H, Nishikawa H, Kimura H, Anayama H, Miyamoto M. 1997. Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience 79:1039-1050.
31. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A. 2003. Long-term measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 30:266-272.
32. Pan J, Konstas AA, Bateman B, Ortolano GA, Pile-Spellman J. 2007. Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. Neuroradiology 49:93-102.
33. Pavlov VA, Tracey KJ. 2005. The cholinergic anti-inflammatory pathway. Brain Behav Immun 19:493-499.
34. Pavlov VA, Tracey KJ. 2006. Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem Soc Trans 34:1037-1040.
35. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, Chavan S, Al-Abed Y, Tracey KJ. 2009. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 23:41-45.
36. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. 2001. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22:153-183.
37. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. 2008. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148:379-397.
38. Roman GC. 2004. Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res 26:454-458.
39. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. 2002. Subcortical ischaemic vascular dementia. Lancet Neurol 1:426-436.
40. Sancesario G, Pietroiusti A, Cestaro B, Fusco FR, Magrini A, Patacchioli FR, Franceschelli L, Galante A. 1997. Mild brain ischemia increases cerebral lipid peroxidation and activates leukocytes in the peripheral blood of rats. Funct Neurol 12:283-291.
41. Santos SC, Vala I, Miguel C, Barata JT, Garcao P, Agostinho P, Mendes M, Coelho AV, Calado A, Oliveira CR, e Silva JM, Saldanha C. 2007. Expression and subcellular localization of a novel nuclear acetylcholinesterase protein. J Biol Chem 282:25597-25603.
42. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, Matthews PM, Fazekas F. 2005. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol 58:610-616.
43. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. 2007. Progression of leukoaraiosis and cognition. Stroke 38:2619-2625.
44. Schmidt-Kastner R, Aguirre-Chen C, Saul I, Yick L, Hamasaki D, Busto R, Ginsberg MD. 2005. Astrocytes react to oligemia in the forebrain induced by chronic bilateral common carotid artery occlusion in rats. Brain Res 1052:28-39.
45. Shibata M, Ohtani R, Ihara M, Tomimoto H. 2004. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 35:2598-2603.
46. Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J. 2004. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 89:337-343.
47. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. 2006. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 20:670-682.
48. Tabet N. 2006. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age Ageing 35:336-338.
49. Tanaka K, Ogawa N, Asanuma M, Kondo Y, Nomura M. 1996. Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion. Brain Res 729:55-65.
50. Teeling JL, Perry VH. 2009. Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 158:1062-1073.
51. Tomimoto H, Ihara M, Wakita H, Ohtani R, Lin JX, Akiguchi I, Kinoshita M, Shibasaki H. 2003. Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol 106:527-534.
52. Wakita H, Tomimoto H, Akiguchi I, Kimura J. 1994. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol 87:484-492.
53. Wakita H, Tomimoto H, Akiguchi I, Kimura J. 1995. Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion. Stroke 26:1415-1422.
54. Wakita H, Tomimoto H, Akiguchi I, Matsuo A, Lin JX, Ihara M, McGeer PL. 2002. Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res 924:63-70.
55. Wakita H, Tomimoto H, Akiguchi I, Lin JX, Ihara M, Ohtani R, Shibata M. 2003. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res 992:53-59.
56. Walker D, Lue LF. 2007. Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr Neuropharmacol 5:232-243.
57. Wang LM, Han YF, Tang XC. 2000. Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 398:65-72.
58. Wang LS, Zhou J, Shao XM, Tang XC. 2002. Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res 949:162-170.
59. Wang Q, Tang XN, Yenari MA. 2007. The inflammatory response in stroke. J Neuroimmunol 184:53-68.
60. Wang RP, Zhao ZK, Hu LL. 2004. Effect of huperzine A on cognitive function and quality of life in vascular dementia: 36 cases for 6 months follow up study. Chinese J Clin Rehab 8:3892.
61. Wang YE, Yue DX, Tang XC. 1986. Anti-cholinesterase activity of huperzine A. Acta Pharmarcol Sin 7:110-113.
62. Wang ZF, Tang XC. 2007. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett 581:596-602.
63. Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC. 2006. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 83:603-611.
64. Wang ZF, Wang J, Zhang HY, Tang XC. 2008. Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem 106:1594-1603.
65. Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. 2006. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke 37:1539-1545.
66. Webster NJ, Green KN, Peers C, Vaughan PF. 2002. Altered processing of amyloid precursor protein in the human neuroblastoma SH-SY5Y by chronic hypoxia. J Neurochem 83:1262-1271.
67. Wessler I, Kirkpatrick CJ. 2008. Acetylcholine beyond neurons: the nonneuronal cholinergic system in humans. Br J Pharmacol 154:1558-1571.
68. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS. 1995. Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmarcol Sin 16:391-395.
69. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ. 1999. Huperzine A in capsules and tablets for treating patients with Alzheimer's disease. Acta Pharmacol Sin 20:486-490.
70. Ye JW, Shang YZ, Wang ZM, Tang XC. 2000. Huperzine A ameliorates the impaired memory of aged rat in the Morris water maze performance. Acta Pharmacol Sin 21:65-69.
71. Zhang ZX, Wang XD, Chen QT, Shu L, Wang JZ, Shan GL. 2002. Clinical efficacy and safety of huperzine A in treatment of mild to moderate Alzheimer's disease, a placebo-controlled, doube-blind, randomized trial. Natl Med J China 82:941-944.
72. Zhong ZG, Liang KZ. 2004. Clinical observation of huperzine A on 29 patients with vascular dementia. J Hainan Med Coll 10:251-252.
73. Zhou J, Fu Y, Tang XC. 2001. Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett 306:53-56.